Skip to main content

Table 1 Characteristics of acute myocardial infarction patients in the study

From: Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients

  STEMI NSTEMI
Diabetic
N = 2820
Non-diabetic
N = 3021
Diabetic
N = 2338
Non-diabetic
N = 1767
Age in years, median (IQR) 58.6 (51.4–66.2) 57.0 (50.5–64.9) 61.2 (54.0–70.0) 58.4 (50.9–66.9)
Male, n (%) 2289 (81.2) 2644 (87.5) 1695 (72.5) 1498 (84.8)
Race, n (%)
 Chinese 1457 (51.7) 1997 (66.1) 1208 (51.7) 1202 (68.0)
 Malay 714 (25.3) 574 (19.0) 550 (23.5) 305 (17.3)
 Indian 601 (21.3) 400 (13.2) 540 (23.1) 230 (13.0)
Past medical history, n (%)
 Hypertension 1854 (65.7) 1266 (41.9) 1876 (80.2) 963 (54.5)
 Diabetes 2142 (76.0) NA 1994 (85.3) NA
 Not on treatment 451 (21.1) NA 257 (12.9) NA
 Diet control 113 (5.3) NA 102 (5.1) NA
 Oral medication 1391 (64.9) NA 1264 (63.4) NA
 Insulin 64 (3.0) NA 153 (7.7) NA
 Oral medication & insulin 123 (5.7) NA 218 (10.9) NA
 Hyperlipidemia 1701 (60.4) 1070 (35.4) 1825 (78.1) 906 (51.3)
MI/PCI/CABG 499 (17.7) 319 (10.6) 963 (41.2) 337 (19.1)
Smoking, n (%)
 Current 1253 (44.9) 1602 (53.3) 750 (32.2) 806 (45.7)
 Former 422 (15.1) 365 (12.1) 468 (20.1) 315 (17.9)
 Never 1118 (40.0) 1039 (34.6) 1113 (47.7) 641 (36.4)
BMI in kg/m2, median (IQR) 25.2 (22.9–27.9) 24.4 (22.2–27.0) 25.6 (23.1–28.9) 24.8 (22.6–27.5)
Glucose in mmol/L, median (IQR) 13.8 (10.5–18.4) 7.8 (6.8–9.4) 12.3 (9.0–16.4) 6.7 (5.8–8.0)
HbA1c in %, median (IQR) 8.0 (6.9–9.9) 5.7 (5.5–6.0) 7.7 (6.8–9.3) 5.7 (5.5–6.0)
Total cholesterol in mmol/L, median (IQR) 4.9 (4.0–5.9) 5.2 (4.5–6.1) 4.7 (3.8–5.7) 5.2 (4.4–6.0)
LDL-cholesterol in mmol/L, median (IQR) 3.1 (2.4–4.0) 3.5 (2.8–4.3) 2.8 (2.2–3.7) 3.5 (2.7–4.2)
HDL-cholesterol in mmol/L, median (IQR) 1.0 (0.8–1.2) 1.1 (0.9–1.3) 1.0 (0.8–1.2) 1.0 (0.9–1.2)
Triglyceride in mmol/L, median (IQR) 1.5 (1.1–2.3) 1.3 (1.0–1.8) 1.7 (1.2–2.5) 1.5 (1.1–2.1)
Haemoglobin in g/dL, median (IQR) 14.6 (13.2–15.7) 14.8 (13.7–15.8) 13.7 (12.1–15.0) 14.5 (13.4–15.4)
Creatinine in µmol/L, median (IQR) 89 (74–112) 90 (77–105) 88 (72–116) 84 (73–97)
Killip class on admission, n (%)
 I 2261 (80.2) 2541 (84.1) 1790 (76.6) 1599 (90.5)
 II 196 (6.9) 126 (4.2) 322 (13.8) 94 (5.3)
 III 130 (4.6) 86 (2.9) 199 (8.5) 52 (2.9)
 IV 233 (8.3) 267 (8.8) 26 (1.1) 21 (1.2)
In-patient medication, n (%)
 Aspirin 2733 (96.9) 2956 (97.9) 2298 (98.3) 1722 (97.5)
 Beta-blocker 2457 (87.1) 2616 (86.6) 2121 (90.7) 1575 (89.1)
 ACEI/ARB 2171 (77.0) 2221 (73.5) 1930 (82.6) 1265 (71.6)
 Lipid lowering drug 2731 (96.8) 2955 (97.8) 2313 (98.9) 1755 (99.3)
 P2Y12 inhibitor 2773 (98.3) 2982 (98.7) 2330 (99.7) 1760 (99.6)
  1. ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin receptor blocker, BMI body mass index, CABG coronary artery bypass grafting, IQR interquartile range, MI myocardial infarction, NA not applicable, NSTEMI non-ST-segment elevation myocardial infarction, PCI percutaneous coronary intervention, SHR stress-hyperglycaemia ratio, STEMI ST-segment elevation myocardial infarction